Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

Key PointsA 16.6 billion euro cash balance gives BioNTech room to fund trials, partnerships, and a $1 billion share repurchase program.

Doc ban tin day du cua Veytics

Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.